Phosphorylation of the endogenous GSK3α (glycogen synthase kinase-3α) at Tyr 279 and GSK3β at Tyr 216 was suppressed in HEK-293 or SH-SY5Y cells by incubation with pharmacological inhibitors of GSK3, but not by an Src-family inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] Our results indicate that the tyrosine phosphorylation of GSK3 is an intramolecular autophosphorylation event in the cells that we have studied and that this modification enhances the stability of the enzyme.
INTRODUCTION
The protein kinase GSK3 (glycogen synthase kinase-3) has been studied intensively in recent years, because it is a central player in several different signal transduction pathways in mammalian cells. A variety of agonists inhibit GSK3 by triggering its phosphorylation at an N-terminal serine residue (Ser 21 in GSK3α and Ser 9 in the GSK3β isoform), and this can be catalysed by several different protein kinases that are switched on in response to signals that activate PI3K (phosphoinositide 3-kinase) or the classical MAPK (mitogen-activated protein kinase) cascade, or elevate cAMP. GSK3 also becomes inhibited by a different mechanism in response to secreted glycoproteins, termed Wnts, a pathway that is critical for the specification of cell fate during embryonic development (reviewed in [1, 2] ).
An intriguing feature of GSK3 is the presence of a phosphotyrosine residue in the 'activation loop' of this enzyme (Tyr 279 in GSK3α and Tyr 216 in GSK3β), a position equivalent to that of the phosphotyrosine residue that is critical for the activity of MAPK [3] . The tyrosine residue in GSK3 is important for activity, because its mutation to phenylalanine or its dephosphorylation decreases activity [3, 4] . However, the mechanism by which the tyrosine residue becomes phosphorylated in cells and whether it plays a regulatory, as opposed to a purely structural role, has been the subject of much debate.
It was initially suggested that the tyrosine phosphorylation of GSK3 was catalysed by another protein kinase, because no phosphate was incorporated into tyrosine when GSK3 isolated from mammalian cells was incubated with MgATP [3] . However, it was reported subsequently that bacterially expressed GSK3β contained some phosphotyrosine, as judged by immunoblotting with a phosphotyrosine-specific antibody, and that, upon incubation with MgATP, further phosphate was incorporated into tyrosine, as well as serine and threonine, residues. [4] . The location of the Abbreviations used: GSK3, glycogen synthase kinase-3; GST, glutathione S-transferase; NGF, nerve growth factor; PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine; PTP, protein tyrosine phosphatase. 1 These authors made equally important contributions to this study. 2 To whom correspondence should be addressed (e-mail p.cohen@dundee.ac.uk).
phosphotyrosine residue(s) in bacterially expressed GSK3 was not determined, but these experiments suggested that the tyrosine phosphorylation of GSK3 might be an autophosphorylation event catalysed by GSK3 itself. On the other hand, genetic evidence supports the view that zaphod kinase-1 (ZAK1) catalyses the tyrosine phosphorylation of GSK3 in Dictyostelium discoideum in response to elevated levels of extracellular cAMP [5] . However, human homologues of ZAK1 do not appear to exist. Thus it is not clear how the findings in Dictyostelium relate to mammals. Nevertheless, other mammalian tyrosine kinases, such as Pyk2 and the Src-related kinase Fyn, have been reported to phosphorylate GSK3 at tyrosine residue(s) in vitro [6, 7] . In the present paper, we have re-investigated the mechanism by which the tyrosine phosphorylation of GSK3 takes place in cells.
EXPERIMENTAL

Materials
Mouse monoclonal antibodies that recognize GSK3α phosphorylated at Tyr 279 , as well as GSK3β phosphorylated at Tyr 216 , were obtained from Upstate Biotechnology (Lake Placid, NY, U.S.A.) and Transduction Laboratories (Lexington, KY, U.S.A.). The less-sensitive Upstate Biotechnology phospho-specific antibody was used to detect the tyrosine phosphorylation of recombinant or transfected GSK3, whereas the more-sensitive antibody from Transduction Laboratories was used to detect phosphorylation of the endogenous GSK3 isoforms in cell extracts. A mouse monoclonal antibody that recognizes the phosphorylated and unphosphorylated forms of GSK3β equally well was purchased from Transduction Laboratories and an antibody (available from Upstate Biotechnology) that recognizes all forms of GSK3α was raised in sheep. These two antibodies were mixed together in order to detect GSK3α and GSK3β simultaneously in cell extracts. Kenpaullone, indirubin, purvalanol, genistein and PP2 [3,4-d] pyrimidine} were purchased from Calbiochem (Beeston, Notts., U.K.) and anisomycin and cycloheximide were from Sigma (Poole, Dorset, U.K.).
{4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo
Site-directed mutagenesis and measurement of GSK3 activity using the standard synthetic peptide substrate YRRAAVPPSPSLSRHSSPHQpSEDEEE (where pS is phosphoserine) was carried out as described previously [8] . GSK3β was expressed as a His 6 -tagged protein in Sf21 cells, or as a glutathione S-transferase (GST)-fusion protein in HEK-293 cells, and was purified as described previously [8] . GSK3β expressed in Sf21 cells was > 95 % pure as judged by SDS/PAGE and had a specific activity of 280 units/mg. GST-GSK3β expressed in Escherichia coli was also purified on glutathione-Sepharose. The full-length enzyme comprised 24 % of the protein, as judged by densitometric analysis of SDS/polyacrylamide gels that had been stained with colloidal Coomassie Blue. After correction for purity, the specific activity was 150 units/mg. All preparations of GSK3 were stored unfrozen at − 20
• C in 50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA, 0.1 % (v/v) 2-mercaptoethanol, 150 mM NaCl, 0.03 % (w/v) Brij-35, 50 % (v/v) glycerol, 1 mM benzamidine and 0.2 mM PMSF. Figure 1A) . None of the catalytically inactive mutants were phosphorylated at Tyr 216 , in contrast with wild-type GSK3. Similar results were obtained when GSK3β was expressed in E. coli; the wild-type enzyme was phosphorylated at Tyr 216 , but a catalytically inactive mutant was not ( Figure 1B) .
RESULTS
Effects of mutation and pharmacological inhibitors on the tyrosine phosphorylation of GSK3
We next examined the effects of two structurally unrelated pharmacological inhibitors of GSK3, Kenpaullone and indirubin, on the tyrosine phosphorylation of GSK3 in HEK-293 cells [9, 10] . These experiments showed that phosphorylation of the endogenous GSK3α on Tyr 279 was greatly decreased after prolonged incubation with either compound, although the amount of GSK3α protein remained constant (Figure 2A) . Phosphorylation of the endogenous GSK3β also decreased, although less markedly. Kenpaullone also induced the dephosphorylation of both GSK3 isoforms in SH-SY5Y cells and PC12 cells (results not shown).
The slow dephosphorylation of GSK3 isoforms in cells treated with GSK3 inhibitors (Figure 2A ) raised the possibility that the observed decrease did not result from dephosphorylation, but from newly synthesized unphosphorylated GSK3 replacing the phosphorylated GSK3 that was already present before the addition of the drugs. To examine this possibility, we studied (Figure 2A ). The presence of cycloheximide or anisomycin did not affect the rate at which phosphate was lost from Tyr 279 /Tyr 216 after the addition of Kenpaullone or indirubin (results not shown). In contrast, c-myc, which is known to have a very short half life, had completely disappeared 4 h after the addition of either protein synthesis inhibitor, as expected (results not shown). These experiments demonstrate that GSK3 isoforms do indeed undergo a slow dephosphorylation at Tyr 279 /Tyr 216 after incubation with GSK3 inhibitors. Kenpaullone and indirubin have been reported to inhibit cyclindependent protein kinases, as well as GSK3 [10] . In order to examine the specificity of the effect, we therefore performed control experiments using purvalanol, an inhibitor of cyclin-dependent protein kinases that does not inhibit GSK3 [11] . Incubation with purvalanol did not decrease the tyrosine phosphorylation of GSK3 ( Figure 2C ). The Src-family tyrosine kinase inhibitor, PP2 [12] , or genistein, a general protein tyrosine kinase inhibitor, also had no effect on the tyrosine phosphorylation of GSK3 isoforms in HEK-293 cells ( Figure 2D ). The concentration of PP2 used in these experiments (10 µM) is two orders of magnitude greater than that needed to completely suppress the phosphorylation of DAPP1 (dual adaptor for phosphotyrosine and 3-phosphoinositides-1), a validated substrate of src-related kinases [13] . At the concentrations used, neither PP2 [11] nor 0.1 mM genistein (results not shown) inhibit GSK3.
If the tyrosine phosphorylation of GSK3 is an autophosphorylation event, then the absence of tyrosine phosphorylation in the catalytically inactive mutants suggested that phosphorylation at Tyr 216 was likely to be an intramolecular process; otherwise one might have expected the catalytically inactive phosphotyrosinedeficient mutants to have been phosphorylated by the endogenous wild-type GSK3 in the transfected cells (Figure 1 ). To investigate this further, we purified the phosphotyrosine-deficient catalytically inactive mutants of GST-GSK3β from HEK-293 cells and incubated them with MgATP and active wild-type His 6 -tagged GSK3β isolated from Sf21 insect cells. These experiments confirmed that the active His 6 -tagged-GSK3β was phosphorylated at Tyr 216 , but was unable to phosphorylate the catalytically inactive mutants at Tyr 216 ( Figure 3A ).
Autophosphorylation of GSK3β at Tyr 216 in vitro
It has been reported that bacterially expressed GSK3β undergoes autophosphorylation at tyrosine, as well as serine and threonine, residues upon incubation with MgATP, but the site(s) of phosphorylation was (were) not determined [4] . We confirmed these results using GSK3β expressed in either E. coli (results not shown) or Sf21 insect cells ( Figure 4A ). Kenpaullone (20 µM) strongly suppressed the autophosphorylation of GSK3β at Tyr 216 in vitro whether GSK3 was expressed in Sf21 cells (Figure 4A) or in E. coli (results not shown), suggesting that it was catalysed by GSK3, and not by a contaminating kinase. The proportion of phosphate attached to Tyr 216 was approx. 10 % of that present in phosphothreonine and phosphoserine together, and the amount of phosphate incorporated into tyrosine never exceeded 0.05 mol/mol of GSK3β, even after prolonged incubation of the Sf21-expressed or E. coli-expressed GSK3β with MgATP or MnATP (results not shown).
If the autophosphorylation of GSK3 is an intramolecular process, then the rate of tyrosine phosphorylation should be independent of enzyme concentration. We therefore incubated 5 µg of GSK3β with Mg[γ -
32 P]ATP in a total volume of either 25 or 250 µl. After 5 min at 30
• C, the GSK3β was precipitated with trichloroacetic acid and was subjected to phosphoamino acid analysis. This experiment showed that the incorporation of phosphate into tyrosine, threonine or serine residues per mol of GSK3β was similar at both dilutions ( Figure 3B ).
To establish whether the radiolabelled phosphate incorporated into GSK3β upon incubation with MgATP was associated with Tyr 216 or another tyrosine residue(s), we digested the autophosphorylated enzyme with trypsin. The tryptic phosphopeptides were resolved by chromatography on a C 18 column ( Figure 4B ) and each 32 P-labelled peptide was subjected to phosphoamino acid analysis. These experiments revealed that phosphotyrosine was present only in the minor phosphopeptide T2 (Figure 4C) , whereas all the other peptides contained phosphothreonine or phosphoserine (results not shown). Peptide T2 was subjected to MS, which revealed the presence of a peptide with a m/z of 1361.6, corresponding to that of the tryptic peptide expected to contain Tyr 216 (GEPNVSYICSR) plus one phosphate. To establish that the phosphotyrosine was really present at Tyr 216 , the 32 P-labelled phosphopeptide was subjected to solid-phase sequencing. This experiment revealed that 32 P radioactivity was released from the peptide after the seventh cycle of Edman degradation ( Figure 4D ), corresponding to the position of Tyr 216 . To try and incorporate more radiolabelled phosphate into Tyr 216 , we first incubated GSK3β (0.2 mg/ml) with high concentrations of protein tyrosine phosphatase 1B (PTP1B; 0.2 mg/ml) to dephosphorylate Tyr 216 . An 8 h incubation at ambient temperature (21
• C) was found to be necessary to achieve nearly complete dephosphorylation of Tyr 216 under these conditions and this was accompanied by an almost complete loss of activity towards the standard peptide substrate (results not shown). However, when the PTP1B-treated GSK3β was incubated with MgATP, and in the presence of sodium vanadate to inhibit the phosphatase, the ability The GSK3β was precipitated with 20 % (w/v) trichloroacetic acid, denatured in SDS, subjected to SDS/PAGE, then transferred on to a PVDF membrane. The bands corresponding to 32 P-labelled GSK3β were excised, then subjected to partial acid hydrolysis followed by electrophoresis on thin-layer cellulose to separate phosphoserine (pS), phosphothreonine (pT) and phosphotyrosine (pY) [17] . The percentage of 32 P radioactivity present as phosphotyrosine relative to the total amount of 32 P-labelled phospho-amino acids was quantified by phosphoimager analysis (% pY).
of GSK3β to autophosphorylate at Tyr 216 was not enhanced, but was actually abolished (results not shown), nor was there any reactivation. This unexpected finding was explained when we incubated GSK3β in the absence of PTP1B and in the presence of sodium vanadate. Under these conditions, GSK3β lost only 30-40 % of its activity after 8 h at ambient temperature, and the level of phosphorylation of Tyr 216 remained stable as judged by immunoblotting ( Figure 5, upper panel) . However, the ability of GSK3β to autophosphorylate at Tyr 216 was lost ( Figure 5 , lower panel). Similar results were obtained in a number of experiments. These results, which imply that molecules of GSK3β lacking phosphate at Tyr 216 are unstable at ambient temperature, are considered further in the Discussion section.
Effects of staurosporine and NGF (nerve growth factor) withdrawal on the tyrosine phosphorylation of GSK3
It has been reported that the induction of apoptosis in SH-SY5Y cells, triggered by the addition of low concentrations of staurosporine (a non-specific protein kinase inhibitor) to the culture medium, stimulates the tyrosine phosphorylation of GSK3 [14] . Similarly, it has been reported that the withdrawal of NGF from PC12 cells triggers the tyrosine phosphorylation of GSK3 [14] . We repeated both of these experiments but, in our hands, there was no increase in the tyrosine phosphorylation of either GSK3 isoform under either of these conditions (Figures 6A and 6B) .
DISCUSSION
Previous work has led to conflicting conclusions as to whether the tyrosine phosphorylation of GSK3 is catalysed by GSK3 itself or by a distinct tyrosine kinase (see the Introduction). Although it is difficult to completely exclude the existence of a protein kinase distinct from GSK3 that targets Tyr 279 of GSK3α and Tyr 216 of GSK3β, we present several new lines of evidence in the present paper that indicate that phosphorylation of these residues is an intramolecular autophosphorylation event in the cells that we have studied. First, we have found that Tyr 216 is not phosphorylated when catalytically inactive mutants of GSK3β are expressed in either HEK-293 cells ( Figure 1A ) or E. coli ( Figure  1B ), in contrast with the wild-type enzyme. Moreover, both GSK3 isoforms become dephosphorylated if cells are incubated with cell-permeant inhibitors of GSK3 (Figure 2A) . Following SDS/PAGE and transfer on to PVDF membranes, the bands corresponding to 32 P-labelled GSK3β were excised and subjected to phospho-amino acid analysis (see legend to Figure  3B ). (B) Same as (A), except that the concentration of GSK3 was 4 µM and autophosphorylation was carried out for 30 min. After SDS/PAGE, the gel piece containing 32 P-labelled GSK3β was excised, digested with trypsin and chromatographed on a Vydac C 18 column, equilibrated in 0.1 % (v/v) trifluoroacetic acid. The column was developed with an acetonitrile gradient (broken line) in 0.1 % trifluoroacetic acid and fractions of 0.1 ml were collected. The 32 P radioactivity is shown by the full line. (C) The tryptic phosphopeptide T2 from (B) was subjected to phospho-amino acid analysis as in (A). (D) The tryptic phosphopeptide T2 from (B) was subjected to solid-phase sequencing to identify the cycle of Edman degradation at which the 32 P radioactivity was released from the peptide [18] .
GSK3β expressed in Sf21 insect cells (Figure 4 ) or E. coli ( Figure 1B ) was already highly phosphorylated at Tyr 216 , as judged by the high specific activity of these preparations, and because incubation with MgATP, which led to the incorporation of 0.03-0.05 mol of phosphate/mol of GSK3β into Tyr 216 did not lead to any observable increase in the total amount of phosphate attached to Tyr 216 , as judged by immunoblotting with the phosphospecific antibody ( Figure 5) . However, the few molecules of GSK3 in the preparation that were not phosphorylated at Tyr 216 did become phosphorylated at this residue upon incubation with MgATP, and this was suppressed by pharmacological inhibition of GSK3 (Figures 3B, 4A and 5 ). It could be argued that even GSK3 purified to near homogeneity from Sf21 cells is contaminated with traces of another insect cell protein tyrosine kinase that can phosphorylate Tyr 216 , but not if Kenpaullone is bound to GSK3 (Figure 3 ). However, it seems inconceivable that such an enzyme exists in E. coli and co-purifies with GSK3, since these bacteria do not normally express GSK3 and are not actually thought to encode any protein tyrosine kinases. Moreover, if the tyrosine phosphorylation of GSK3β was catalysed by another protein kinase, the rate of phosphorylation of Tyr 216 should decrease upon dilution, which did not occur ( Figure 3B ). This finding, together with the observation that wild-type GSK3β cannot tyrosine phosphorylate catalytically inactive mutants of GSK3β that lack phosphate at Tyr 216 (Figure 3) , indicates that the phosphorylation of Tyr 216 in vitro is an intramolecular autophosphorylation. Our findings also demonstrate that the phosphorylation of Tyr 216 is not required for GSK3β to become catalytically active, at least not when it is phosphorylating itself at Tyr 216 . To try to incorporate more phosphate at Tyr 216 , we first removed the phosphate already present at Tyr 216 by prolonged incubation of GSK3β with PTP-1B, but, to our surprise, this incubation actually destroyed the ability of GSK3β to autophosphorylate at Tyr 216 . Further experiments revealed that it was the incubation at ambient temperature, and not the dephosphorylation of Tyr 216 , that was responsible for this phenomenon, because the same result was obtained if PTP1B was omitted ( Figure 5 ). These observations imply that molecules of GSK3β lacking phosphate at Tyr 216 rapidly lose the ability to autophosphorylate at Tyr 216 when incubated at ambient temperature in vitro, suggesting a role for this modification in stabilizing the enzyme. In contrast, the molecules of GSK3β phosphorylated at Tyr 216 were much more stable at ambient temperature, losing only 30-40 % of their activity towards the standard synthetic peptide substrate after 8 h. These molecules also retained the ability to autophosphorylate at serine and threonine residues ( Figure 5 ).
In the mammalian cells that we have studied, it appears that GSK3 isoforms are highly, if not fully, phosphorylated at Tyr 279 /Tyr 216 . This is indicated both by the report that GSK3 purified from mammalian cells does not autophosphorylate on . The reaction was terminated by the addition of SDS and, following SDS/PAGE and transfer on to PVDF membranes, the bands corresponding to 32 P-labelled GSK3β were excised and subjected to phospho-amino acid analysis (see the legend to Figure 3B ). tyrosine residues [3] , and because incubation of mammalian cells for up to 8 become dephosphorylated in mammalian cells that we have not studied and/or in response to agonists we have not examined, we have been unable to confirm any of the reports in the literature that the tyrosine phosphorylation of GSK3 changes dynamically in response to extracellular signals. For example, the phosphorylation of GSK3β at Tyr 216 was reported to decrease when cells were exposed to insulin [15] . However, we were unable to detect any change in the level of phosphorylation of Tyr 216 when HEK-293 cells were stimulated with insulin or IGF-1 (insulinlike growth factor-1) [16] . More recently, insulin was reported to stimulate a transient phosphorylation of GSK3β at Tyr 216 in SH-SY5Y cells, and phosphorylation was accompanied by enhanced association of GSK3β with the tyrosine kinase Fyn [6] . We repeated these experiments, but were again unable to show a significant increase in Tyr 216 phosphorylation under these conditions (results not shown). Moreover, PP2, a potent inhibitor of Src-family protein kinases, did not decrease the tyrosine phosphorylation of GSK3 in HEK-293 cells ( Figure 2B ) or SH-SY5Y cells (results not shown).
It has also been reported that the level of phosphorylation of GSK3β at Tyr 216 increases in neuronal PC12 cells or SH-SY5Y neuroblastoma cells in response to apoptotic stimuli, such as the removal of NGF from the medium or exposure to staurosporine [14] . However, we were unable to detect any alteration in the tyrosine phosphorylation of GSK3α or GSK3β under these conditions either (Figures 6A and 6B) .
We have examined a number of commercially available phosphospecific antibodies reported to recognize GSK3 isoforms phosphorylated at Tyr 279 and Tyr 216 , including those used in the studies cited above. However, in our hands, only the antibody from Transduction Laboratories was sufficiently specific and sensitive to unambiguously detect the endogenous tyrosinephosphorylated GSK3 isoforms. Other commercially available antibodies recognized numerous bands in the cell lysates, some of which are likely to be other tyrosine-phosphorylated proteins. It is possible that one or more of these proteins has been mistakenly assumed to be a GSK3 isoform in some previous studies, leading to erroneous conclusions being drawn.
